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Haibo Zhu1†, Jie Tang1†, Mingjie Tang2† and Haikang Cai1*Abstract
Objective: SOX9 plays an important role in bone formation and tumorigenesis. However, its involvement in
osteosarcoma is still unclear. The aim of this study was to investigate the expression pattern and the clinical
significance of SOX9 in human osteosarcoma.
Methods: SOX9 mRNA and protein expression levels were detected by RT-PCR and Western blot assays, respectively,
using 30 pairs of osteosarcoma and noncancerous bone tissues. Then, immunohistochemistry was performed to
analyze the association of SOX9 expression in 166 osteosarcoma tissues with clinicopathological factors or survival
of patients.
Results: SOX9 expression at mRNA and protein levels were both significantly higher in osteosarcoma tissues than
those in corresponding noncancerous bone tissues (both P < 0.001). Immunohistochemical staining indicated that
SOX9 localized to the nucleus and high SOX9 expression was observed in 120 of 166 (72.3%) osteosarcoma specimens.
In addition, high SOX9 expression was more frequently occurred in osteosarcoma tissues with advanced clinical stage
(P = 0.02), positive distant metastasis (P = 0.008) and poor response to chemotherapy (P = 0.02). Osteosarcoma patients
with high SOX9 expression had shorter overall survival and disease-free survival (both P < 0.001). Furthermore, the
multivariate analysis confirmed that upregulation of SOX9 was an independent and significant prognostic factor
to predict poor overall survival and disease-free survival (both P = 0.006).
Conclusions: Our data show for the first time that SOX9 is upregulated in aggressive osteosarcoma tissues
indicating that SOX9 may participate in the osteosarcoma progression. More importantly, SOX9 status is a useful
prognostic factor for predicting the prognosis of osteosarcoma, suggesting that SOX9 may contribute to the
optimization of clinical treatments for osteosarcoma patients.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1318085636110837.
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Osteosarcoma, a kind of highly aggressive neoplasm arising
from long bones, is the most common primary malignancy
in children and adolescents [1]. Although it is a relative
uncommon cancer with an estimated worldwide incidence
of 2 ~ 3 cases per million persons per year, osteosarcoma* Correspondence: caihai_kang@163.com
†Equal contributors
1Orthopaedics Department, Xuhui central hospital, No. 966, Middle Huaihai
Road, Shanghai 200031, China
Full list of author information is available at the end of the article
© 2013 Zhu et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.predominately arises in bone during periods of rapid
growth and has a predilection to affect adolescents
and young adults, and if untreated it is fatal [2]. Char-
acteristically, osteosarcoma often occurs from low-grade
lesions with low malignant potential, through to high-
grade lesions with the potential for distant metastasis,
and it metastasizes preferentially to the lung [3]. Despite
recent advances in modern treatment protocols combin-
ing chemotherapy, surgery, and sometimes radiotherapy,
the 5-year overall survival and disease-free survival. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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[4]. In order to give effective treatment to each patient,
accumulating studies have tried to predict the clinical
course of osteosarcoma patients by assessing the response
to chemotherapy histologically or by determining clinical
stage. However, these features have limited utility in terms
of predicting the clinical course of osteosarcoma patients,
which suggests that different genetic mechanisms may
be operating and altering the response to chemotherapy
and metastatic capability of osteosarcomas with the
same clinicopathological features [5]. Therefore, molecular
pathogenesis of osteosarcoma, which can identify tumor
pathways and specific mediators, should be clarified in
order to provide insight into tumorigenesis and tumor
progression, and subsequently develop novel approaches
for treating osteosarcoma.
As a developmental transcription factor, Sex deter-
mining region Y (SRY)-related high mobility group
(HMG)-box 9 (SOX9) plays a vital role in the regulation
of sex determination, cartilage development, intestinal
differentiation and adult progenitor cell pool mainten-
ance [6]. SOX9 shares 70% amino acid homology to
SRY through its HMG box, the domains of which are
involved in the regulation of DNA-dependent processes,
such as transcription and replication [7]. In humans,
SOX9 heterozygous mutations result in campomelic
dysplasia, a syndrome characterized by severe skeletal
malformations, defects in the central nervous system
and several other organs, frequent XY female sex reversal,
and perinatal lethality [8]. Duplications of the SOX9
gene or its deliberate mis-expression have been linked
with XX male sex reversal and fibrosis-related disorders
and suggest that dysregulation of the gene can cause
disease. In particular, recent studies have indicated the
emerging role of SOX9 in various human cancers.
SOX9 has been found to be overexpressed in gastric
carcinoma, non-small cell lung cancer, prostate cancer,
breast cancer, pancreatic ductal adenocarcinoma, glioma,
colorectal cancer and ovarian cancer [9-16]. In contrast,
SOX9 may function as a tumor suppressor, at least in
some melanomas [17]. These findings suggest that
SOX9 may play different roles in various types of
malignancies. However, very little is known about
SOX9 in human osteosarcoma. Since it has been
demonstrated to be an important regulator of the
bone development and chondrocyte phenotype, we
hypothesized that SOX9 may be a candidate marker
for osteosarcoma progression. In the current study,
we conducted RT-PCR, Western blot and immunohisto-
chemistry assays to determine the expression patterns
of SOX9 at both mRNA and protein levels in osteo-
sarcoma tissues. We further revealed the clinical sig-
nificance of the aberrant expression of SOX9 in this
disease.Materials and methods
Patients and tissue samples
This study was approved by the Research Ethics Commit-
tee of Shanghai Sixth people's hospital, Shanghai Changhai
hospital, Shanghai East hospital, Zhujiang Hospital, and
Xuhui central hospital, China. Written informed consent
was obtained from all of the patients. All specimens were
handled and made anonymous according to the ethical
and legal standards.
For RT-PCR and Western blot assays, 30 primary
osteosarcoma and corresponding noncancerous bone
tissue samples from the same specimens were immedi-
ately frozen in liquid nitrogen and stored at −80°C until
use. For immunohistochemistry analysis, 166 primary
osteosarcoma and corresponding noncancerous bone
tissue samples from the same specimens were collected
from the Department of Pathology, Shanghai Sixth people's
hospital, Shanghai Changhai hospital, Shanghai East
hospital, Zhujiang Hospital, and Xuhui central hospital,
China, from January 1998 to March 2008. No patients had
received blood transfusion, radiotherapy, or chemotherapy
before surgery. Clinical stage of these osteosarcoma
patients were classified according to the sixth edition
of the tumor-node-metastases (TNM) classification of
the International Union against Cancer (UICC). The
clinicopathological information of the patients is shown in
Table 1. Immunostainings were performed on archived
paraffin wax embedded biopsy specimens.
All 166 osteosarcoma patients received follow-up. The
median follow-up was 87 months (range: 10–152 months).
During the follow-up period, 66 patients (66/166, 39.8%)
died of disease. Distant metastases developed in 42
patients at a mean of 13.8 months (range 3–46 months)
after the original diagnosis. Of these patients, 9 had
bone metastases and 36 had lung metastases (3 patients
had both bone and lung metastases). The median overall
and disease-free survival of patients was 31 months (95%
confidence interval [CI], 30.1-42.9 months) and 25 months
(95% CI, 23.7-35.2 months), respectively.
Real-time quantitative RT-PCR Assay
The expression levels of SOX9 mRNA in osteosarcoma
and corresponding noncancerous tissues were detected
by real-time quantitative RT-PCR assay according to our
previous study [18]. Briefly, total RNA was extracted from
tissues using TRIzol (Invitrogen, Carlsbad, CA) according
to the manufacturer’s protocol. The reverse transcription
reaction was performed using high-capacity cDNA syn-
thesis kit (Applied Biosystems, Foster City, CA). Equal
cDNA amounts from each sample were amplified using
the following primers: for human SOX9, forward primer,
5'- CGA AAT CAA CGA GAA ACT GGA C -3', and
reverse primer, 5'- ATT TAG CAC ACT GAT CAC AC
G -3'; for human glyceraldehyde 3-phosphate dehydrogenase
Table 1 Correlation of SOX9 expression with clinicopathological features of osteosarcoma
Clinicopathological features No. of cases SOX9 expression P
High (n, %) Low (n, %)
Age
<55 72 50 (69.4) 22 (30.6) NS
≥55 94 70 (74.5) 24 (25.5)
Gender
Male 96 70 (72.9) 26 (27.1) NS
Female 70 50 (71.4) 20 (28.6)
Tumor size (cm)
>8 88 62 (70.5) 26 (29.5) NS
≤8 78 58 (74.4) 20 (25.6)
Anatomic location
Tibia/femur 103 76 (73.8) 27 (26.2) NS
Elsewhere 63 44 (69.8) 19 (30.2)
Serum level of lactate dehydrogenase
Elevated 90 70 (77.8) 20 (22.2) NS
Normal 76 50 (65.8) 26 (34.2)
Serum level of alkaline phosphatase
Elevated 108 80 (74.1) 28 (25.9) NS
Normal 58 40 (69.1) 18 (30.9)
Clinical stage
IIA 68 32 (47.1) 36 (52.9) 0.02
IIB/III 98 88 (89.8) 10 (10.2)
Distant metastasis
Absent 124 78 (62.9) 46 (37.1) 0.008
Present 42 42 (100.0) 0 (0)
Response to chemotherapy
Good 68 32 (47.1) 36 (52.9) 0.02
Poor 98 88 (89.8) 10 (10.2)
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TTG AC-3', and reverse primer, 5'-ATG AGG TCC ACC
ACC CTG TT-3'. Each sample was examined in triplicate
and the amounts of the PCR products produced were
non-neoplasticized to GAPDH which served as internal
control.
Western blot analysis
The expression levels of SOX9 protein in osteosarcoma
and corresponding noncancerous bone tissues were
detected by Western blot analysis according to our
previous study [18]. Briefly, the tissues were harvested
by scraping and lysed using modified radio immuno-
precipitation assay buffer (50 mM Tris–HCl, pH 7.4),
1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl,
1 mM ethylenediaminetetraacetic acid (EDTA), protease
inhibitor cocktail complete. The protein content was
determined according to Bradford’s method. Equal proteinamounts from each sample were separated electrophoret-
ically on 7.5% SDS-polyacrylamide gels and transferred
onto polyvinylidene difluoride membranes (Roche; Basel,
Switzerland). The membranes were probed with monoclo-
nal mouse antihuman SOX9 (sc-166505, 1:200, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The expression
level of SOX9 was determined by incubating the
membranes with horseradish peroxidase-conjugated
anti-mouse immunoglobulin G (1:3000 dilution) and
enhanced chemiluminescence reagent (Pierce; Minneapolis,
MN, USA) according to the manufacturer’s protocol.
Anti-β-actin mouse monoclonal antibody (1:1000 dilu-
tion: Sigma; St Louis, MO, USA) was used as a loading
control. Each sample was examined in triplicate and
the expression level of SOX9 protein was evaluated as
an optical densitometry (OD) ratio that was scored as
the densitometry of SOX9 relative to the densitometry
of β-actin.
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The sub-cellular localization and expression levels of
SOX9 protein in osteosarcoma and corresponding
noncancerous bone tissues were detected by immu-
nohistochemistry analysis using paraffin-embedded
specimens from 166 patients with osteosarcoma
according to our previous study [18]. Briefly, the
paraffin-embedded tissues were cut at 3μm and stained
following being dried on ProbeOn Plus (Fisher Scien-
tific International, Hampton, NH, USA). The slide to
which a paraffin section was attached went through
deparaffinization and hydration, and was then treated
with a solution of Peroxidase-blocking reagent (DAKO,
Hamburg, Germany) to exhaust endogenous peroxidase
activity. To inhibit non-specific antigen-antibody
reactions possible in immunohistochemical staining,
reaction was done using a protein blocker (Research
Genetics, Huntsville, AL, USA) for 5 min and the
slide was washed thoroughly with water. The slides
were incubated overnight with the primary SOX9
antibody (mouse monoclonal antibody, sc-166505,
1:200, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) at 4°C. Secondary antibody for the detection of
primary antibody was reacted for 10 min using anti-
mouse IgG (Sigma, St. Louis, MO, USA) to which
biotin was attached, and then washed with buffer
solution and reacted with horseradish peroxidase for
10 min. After hematoxylin contrast staining, the
slide was enclosed with Universal Mount (Research
Genetics) and examined. In each immunohistochemis-
try run, noncancerous bone tissues were used as con-
trol tissues and non-immune IgG was also used as
negative control antibody for immunohistochemical
staining.
Assessment of immunohistochemical staining was
evaluated by two independent pathologists who were
blinded to the clinicopathological parameters and
clinical outcomes of the patients. The SOX9-positive
cells showed immunoreactivity in the nucleus of
tumor cells. The number of SOX9 positive-staining
cells showing immunoreactivity in ten representative
microscopic fields was counted and the percentage of
positive cells was calculated. The percentage scoring
of immunoreactive tumor cells was as follows: 0 (0%),
1 (1-10%), 2 (11-50%) and 3 (>50%). The staining
intensity was visually scored and stratified as follows:
0 (negative), 1 (weak), 2 (moderate) and 3 (strong). A
final immunoreactivity scores (IRS) was obtained for
each case by multiplying the percentage and the
intensity score. The median of IRS for all examined
samples was 5.0. Thus, the SOX9 protein expression
levels were further analyzed by classifying IRS values
as low (based on a IRS value less than 5.0) and as
high (based on a IRS value greater than 5.0).Statistical analysis
The software of SPSS version13.0 for Windows (SPSS
Inc, IL, USA) and SAS 9.1 (SAS Institute, Cary, NC)
was used for statistical analysis. Continuous variables
were expressed as X  s . Spearman rank correlation is
used to analyze the correlation between SOX9 mRNA
expression and SOX9 protein expression. The Chi-square
test was used to show differences of categorical variables.
Patient survival and their differences were determined by
Kaplan–Meier method and log-rank test. Cox regression
(Proportional hazard model) was adopted for multivariate
analysis of prognostic factors. Differences were considered
statistically significant when P was less than 0.05.Results
Upregulation of SOX9 at mRNA and protein levels in
human osteosarcoma tissues
As shown in Figure 1A, the expression levels of SOX9
mRNA were found to be distinctly increased in os-
teosarcoma tissues compared to noncancerous bone
tissues. The statistic analysis showed that the relative
level of SOX9 mRNA expression in osteosarcoma tis-
sues (mean ± SD: 2.4 ± 0.6) was significantly higher
than that in corresponding noncancerous bone tissues
(mean ± SD: 0.9 ± 0.1; P < 0.001, Figure 1B). Similarly,
the relative expression levels of SOX9 protein in
osteosarcoma tissues (mean ± SD: 2.1 ± 0.4) tended to
be significantly higher than that in corresponding non-
cancerous bone tissues (mean ± SD: 0.6 ± 0.08; P <
0.001; Figure 1C and D). More importantly, there was
a significant correlation between SOX9 mRNA expres-
sion and SOX9 protein expression (r = 0.8; P < 0.001;
Spearman rank correlation analysis).Upregulation of SOX9 protein associates with advanced
clinicopathological features of osteosarcoma
SOX9 positive staining was localized in the cell
nucleus in primary osteosarcoma and corresponding
noncancerous bone tissues, which was consistent with
the previous study of Won et al. [19]. Of 166 osteosar-
coma specimens, 120 (72.3%) highly expressed SOX9.
Then, we analyzed the associations of SOX9 expres-
sion with various clinicopathological parameters of
osteosarcoma tissues. As shown in Table 1, high SOX9
expression was more frequently occurred in osteosar-
coma tissues with advanced clinical stage (P = 0.02),
positive distant metastasis (P = 0.008) and poor re-
sponse to chemotherapy (P = 0.02). No significant dif-
ference was observed between the expression of SOX9
and patients’ age, gender, tumor size, anatomic loca-
tion, serum levels of lactate dehydrogenase and alka-
line phosphatase, and response to chemotherapy.
Figure 1 SOX9 mRNA and protein expression in 30 osteosarcoma and corresponding noncancerous bone tissues were respectively
detected by real-time quantitative RT-PCR assay and Western blot analysis. (A) Expression levels of SOX9 mRNA in osteosarcoma tissues
and noncancerous bone tissues. ((B) A graphical representation of the SOX9 mRNA level expression profiles in A). (C) Expression levels of SOX9
protein in osteosarcoma tissues and noncancerous bone tissues. (D) A graphical representation of the SOX9 protein level expression profiles in
(C). 'N' refers to noncancerous bone tissues; 'T' refers to osteosarcoma tissues.
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prognosis in patients with osteosarcomas
Using Kaplan–Meier method and log-rank test, the overall
survival (OS, Figure 2A, P < 0.001) and disease-free
survival (DFS, Figure 2B, P < 0.001) of osteosarcomaFigure 2 Kaplan–Meier curves for patients with osteosarcoma. Overall
by low and high expression of SOX9 in patients with osteosarcoma. The
overall survival and disease-free survival rates than those with low SOX9tissues with high SOX9 expression were both significantly
shorter than those with low SOX9 expression (both P <
0.001). Besides, the survival benefits were also found in
those with smaller tumor size (both P = 0.03), higher
clinical stage (P = 0.01 and 0.006, respectively), withoutsurvival (A) and disease-free survival (B) curves for two groups defined
patients with high SOX9 expression had a significantly worse 5-year
staining (both P < 0.001).
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and better response to chemotherapy (both P = 0.02)
for OS and DFS.
Multivariate Cox regression analysis enrolling above-
mentioned significant parameters revealed that SOX9
expression (RR 6.9, 95% CI, 1.5-14.8 P < 0.001), clinical
stage (RR 2.3, 95% CI, 1.1–7.0, P = 0.02), distant metastasis
status (RR 3.7, 95% CI, 1.9–9.8, P = 0.01), and response
to chemotherapy (RR 2.6, 95% CI, 1.5–8.2, P = 0.02) were
independent prognostic markers for OS of patients with
osteosarcoma (Table 2). Turning to DFS, SOX9 expression
(RR 6.1, 95% CI, 1.3-13.9, P < 0.001), clinical stage (RR 1.8,
95% CI, 0.7–8.1, P = 0.03) and metastasis status (RR 2.9,
95% CI, 1.3–10.6, P = 0.02) were also independent prog-
nostic markers for DFS of patients with osteosarcoma
(Table 2).
Discussion
Many molecular markers have proven prognostic value
in osteosarcoma. It would be helpful if these markers
were used as objective instruments for predicting the
chance of survival or chemotherapy response, especially
early in treatment, preferably even before surgery. The
major finding of our study is that the upregulation of
SOX9 expression is associated with the progression of
osteosarcoma. To the best of our knowledge, the current
study represents the first demonstration that SOX9
mRNA and protein are upregulated in osteosarcoma and
that this degree of upregulation promotes advanced tumor
progression.
The SOX gene family, which encodes transcription
factors that bind to high-mobility group domains of
DNA, has been found to share homology with the HMG
box of the SRY [20]. Members of this family play critical
roles in embryonic development, cell fate determination,
differentiation, and proliferation [21]. SOX9, together with
SOX8 and Sox10, belongs to the subgroup of the SOX E
family [22]. It was originally known as a chondrogenic
transcription factor involved in bone formation and testis
development, whereas its mutations are the cause of
the human disease campomelic dysplasia, a form of
dwarfism characterized by extreme cartilage and bone
malformation, which is frequently associated with XY
sex reversal [23]. Since it is well recognized that genes
and pathways critical for development may also playTable 2 Multivariate survival analysis of OS and DFS in 166 p
Variables OS
RR 95% CI
SOX9 expression 6.9 1.5-14.8
Clinical stage 2.3 1.1-7.0
Distant metastasis status 3.7 1.9-9.8
Response to chemotherapy 2.6 1.5-8.2important roles in cancer development and progression,
it is not surprising that SOX9 is involved in cancers.
Zhou et al. [9] reported that the elevated expression of
SOX9 may be related with the progression of gastric
carcinoma; Chakravarty et al. [10] demonstrated that
cytoplasmic SOX9 may serve as a valuable prognostic
marker for invasive ductal carcinomas and metastatic
breast cancer, and its significant correlation with breast
tumor cell proliferation implied that SOX9 may directly
contribute to the poor clinical outcomes associated with
invasive breast cancer; Vidal et al. [11] found that SOX9
expression was a general feature of basal cell carcinoma
and adnexal skin neoplasms; Lü et al. [12] suggested that
SOX9 expression may be upregulated in colorectal cancer
and strong SOX9 expression may be an independent
adverse prognosticator in this cancer; Huang et al. [13]
indicated that Sox9 may be required for prostate devel-
opment and prostate cancer initiation; Zhou et al. [14]
reported that SOX9 upregulation may be an independent
prognostic indicator for the survival of patients with
non-small cell lung cancer; Tanaka et al. [15] also found
that SOX9 might contribute to carcinogenesis in pan-
creatic ductal adenocarcinoma and intraductal papillary
mucinous neoplasm. In contrast, Passeron et al. [17]
analyzed SOX9 expression in melanoma and discovered
that SOX9 expression gradually decreased according to
disease progress from normal skin to nevi, primary
melanoma, and metastatic melanoma. Together, these
observations suggest that SOX9 may be an attractive
candidate marker that is involved in the tumor initiation
and tumor progression, and it may play different roles
depending on cancer types.
In the current study, there are four points of our findings.
At first, SOX9 was up-regulated in human osteosarcoma
tissues compared with noncancerous bone tissues at
both mRNA and protein levels. However, Won et al. [19]
in 2009 produced 48 formalin-fixed, paraffin-embedded
tissue microarrays containing osteosarcoma tissue cores
for immunohistochemical staining of SOX9. They ob-
served negative immunostaining of SOX9 in 37 (77.1%)
cores. The discrepancy between our data and this previous
study may be caused by two reasons: (1) this previous
study included only a small number of osteosarcoma
tissues; (2) the heterogenicity of osteosarcoma tissues
included in different studies. Secondly, the increasedatients with osteosarcoma
DFS
P RR 95% CI P
<0.001 6.1 1.3-13.9 <0.001
0.02 1.8 0.7-8.1 0.03
0.01 2.9 1.3-10.6 0.02
0.02 0.9 0.3-1.7 0.6
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correlated with aggressive clinicopathological features;
Thirdly, the results of Kaplan-Meier analyses shown
that osteosarcoma tissues with high SOX9 expression
tend to have shorter overall survival and disease-free
survival. Finally, the multivariate analysis clearly dem-
onstrated that SOX9 overexpression was a statistically
significant risk factor affecting both overall survival and
disease-free survival in osteosarcoma patients, suggesting
that SOX9 expression could be a valuable marker of
tumor progression and prognosis of osteosarcoma.
Conclusions
In conclusion, our data show for the first time that
SOX9 is upregulated in aggressive osteosarcoma tissues
indicating that SOX9 may participate in the tumor
progression of osteosarcoma. More importantly, SOX9
status is a useful prognostic factor for predicting the
prognosis of osteosarcoma, suggesting that SOX9 may
contribute to the optimization of clinical treatments
for osteosarcoma patients.
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